Good minutes affirm and leadership achieving, team all with and great Thanks everyone. to talk are few progress going to It's about and pride to take that employees Michael. our appreciation evening strategy a forward. our like so I'd for our
I'm outperforming on our multiple business is pleased fronts. that to say
the track the continued As on we innovation are well-positioned our achieve growth and or year exceed and in area, enter second XXXX for of goals, we to we're future.
before people support significant with more than to creating and approved with treating future continues CF to revenue medicines, which We're investment our to ever drive growth medicines.
specialty ongoing We have five rapidly evaluating programs development have different and pipeline seven transformative beyond now growing spanning diseases. our we potentially medicines CF,
established complementing also multiple and over at engine. our have We research aim collaborations past internal acquisitions the new productive year
CF. is First
for regulatory CF nine XXXX approvals label progress our alone, expansions has in we new In globally. extraordinary. medicines CF received Our or been have
over outside III patients. for FDA, the submission create the of agreements combination involving to-date New our program of medicines the and X,XXX the week, reimbursement completed for U.S. tezacaftor decades. new new efforts the in past our to Drug most U.S. the reached nearly and announced ivacaftor triple milestones in the last triple the CF marking regimens XX just VX-XXX Application we to And combination countries two We Phase significant
in triple the the measures studies. in lung VX-XXX III Phase magnitude disease regimen our among any were ever function data unprecedented, we announced of improvements The seen were May in that and highest other of showing for the combination CF
the progressive our disease. CF debilitating combination their is share the underlying patients medicine within moved a treat for urgency are NDA of and a VX-XXX the the waiting CF of data. We to triple therefore receiving to just final and to complete of quickly cause we who new weeks
are current Vertex. from to patients reimbursement on we the provide wherever agreements for that portfolio also with new U.S., reaching agreements And will our future CF possible, access focused are Outside CF we medicines. seeking innovations
CF, our pipeline and advancing Beyond rapidly. is expanding
specialty antitrypsin We across beta-thalassemia. serious have new development disease transformative deficiency, five sickle clinical and kidney areas, APOLX-mediated potential including alpha-X disease diseases, and pain, pain, medicines seven cell
our of We our are external acquisition and expanded of future CRISPR therapies the the breakthrough collaboration investment and toolkit to example for diseases increasing new the are specific recent these interested of DMX. Exonics we're and medicines build in. efforts completed genetic Therapeutics DMD Most also recently with and to development Therapeutics develop
We cutting-edge months over aligned fields years. with promising development more as further these provide highly and of business are plan the expand and pipeline and types transformative shown enable with coming medicines our These execute that that scientific diseases preclinical to us have to of in results us of also agreements expertise integrate our candidates strategy. we technology
XXXX. first in Our performance medicines by strategy to create strong scientific is the half our working innovation serial as by continued investing demonstrated of in
in clinical our both have a to in evident own future growth. of directed significant risk-lowering collaborations substantial fuel progression to invest and potential R&D allows through commercial internally investments pipeline success we The new achieve and us in our pipeline, of data results our in our programs Importantly, the XXXX. several and are the our externally highly to in
Before a where about words I will leadership months I remarks, that eight President Vertex's from transition new Executive CEO. now, like and end and few will happen I'd the to will prepared Chairman say my become become Reshma
me been has team say since First, has proud let time. Vertex during honor a that I'm tremendous what never this and stronger. pleasure lead the accomplished very XXXX. that company it's to been of
decade our to CF grow clinical Our of we growing vast and then serious rapidly to multiple deliver worldwide pipeline and diseases. business is on stage next elexacaftor other bring as for continue majority we'll the patients the and
now Based medicines upon deliver transformative to diseases. CF, and to serious with more both external internal in success invest in to strength more patients even we our have financial the innovation
have perfect into for the years, an I she factors senior with that to we Vertex succeed fully track against of several know future. proven the lead as worked these me us outstanding success. position is us long-term record a choice leadership our and Together, to for the closely CEO with executing Finally, Reshma last team us and differentiate strategy. prepared Having
she a innovation culture our as our outstanding position inclusive scientist, commitment well a of deep has science. as As serial strategy of
strategy She deliver with is a and leader strong an against excellent a results. proven communicator to our ability and execute collaborative
first of transformative driving Importantly, impact putting to she record a in innovation has lives. on a patients' track have patients
smooth Board several rid getting know, of this, all the plan both continuity. and and probably yet, you challenges that is one companies. Recognizing would course operational biggest biotech on of the for you for worked aren't undisrupted succession and been succession quite ensure the years as I Of strategic historically
and the to to Executive in a plan, through I'm Chairman, role Reshma this playing our transition a As smooth XXXX. QX part supporting as team company continued active forward looking of
the where federal I established have I last access of continuing deals Specifically, products; to years. relationships Reshma to the business government secure Investor with with engage our seven site will agreed building research progresses. company done forward state, new and maintain four I get have look that in active development, over role I external and areas and company; relations genetic innovation international our therapies; Relations an to dedicated helping affairs you as to levels Boston to and important public in the and
I'll now Reshma. turn to call over the
